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CRACR2A protein is described in T cells as an EF-hand-containing modulator of calcium-release-activated
calcium (CRAC) channels. Here we sought relevance to calcium entry of endothelial cells. Unexpectedly,
short interfering RNA designed to deplete CRACR2A had no effect on CRAC channels in endothelial cells
but reduced the abundance of a protein with about twice the mass of CRACR2A. Reference to gene
sequence data indicated the potential for a variant transcript encoding a C-terminal Rab GTPase
extension of CRACR2A. Full-length cloning demonstrated expression of the long variant in endothelial
cells. It was designated CRACR2A-L. Sequence analysis suggested it to be a previously unrecognised
member of the Rab GTPase family. It made a positive contribution to endothelial tube formation. The data
suggest that endothelial cells contain a long variant of CRACR2A which is an EF-hand-containing Rab
protein that lacks impact on CRAC channels.
 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/3.0/).1. Introduction with 2% foetal calf serum (FCS) and growth factor bullet kit (Lonza).Ca2+-release-activated Ca2+ (CRAC) channels arising from Orai1
proteins mediate store-operated Ca2+ entry when STIM1 proteins
sense Ca2+-depletion of the smooth endoplasmic reticulum [1,2].
A modulator of CRAC channels in T cells is CRACR2A, a 46 kDa
cytosolic protein with functional N-terminal EF-hands [3].
Orai1 and STIM1 proteins are widely expressed and Ca2+ entry
mediated by CRAC channels is suggested to be functionally impor-
tant in many cell types. In endothelial cells, a positive role has been
suggested in cell migration induced by the key mediator vascular
endothelial growth factor [4]. Here we sought the relevance of
CRACR2A to endothelial cells and CRAC channels of these cells.
2. Materials and methods
2.1. Cell culture
Human umbilical vein endothelial cells (HUVECs) (Lonza) were
maintained in endothelial growth medium (EGM-2) supplementedExperiments were performed on passage 2–8 cells. Cells were
maintained at 37 C in a 5% CO2 incubator. Other endothelial cells
were from PromoCell and maintained similarly to HUVECs.
2.2. Intracellular Ca2+ measurement
HUVECs were seeded in non-coated 96-well plates (NUNC) and
incubated for 1 h in 2 lM fura-2 AM in standard bath solution
(SBS) at 37 C in the presence of 0.01% pluronic acid (Invitrogen).
SBS contained (mM): NaCl 130, KCl 5, MgCl2 1.2, CaCl2 1.5, D-glucose
8, HEPES 10; Osmolality adjusted to 290 mOsm with NaCl; pH
titrated to 7.4 with 4 M NaOH. Ca2+ free solution was SBS without
added Ca2+. Cells were washed three times with SBS before
measurements were made at room temperature (21 ± 2 C) on a
96-well ﬂuorescence plate reader (FlexStation II384, Molecular
Devices). Fura-2 was excited at 340 and 380 nm and emission
was collected at 510 nm. Readings were made every 10 s. The
change (D) in intracellular Ca2+ concentration was indicated as
the ratio of fura-2 emission intensities for 340 nm and 380 nm
excitation (DF ratio).
2.3. Short interfering (si) RNA
HUVECs were transfected at 90% conﬂuence with 20 nmol/L
of CRACR2A siRNA or Orai1 siRNA (Applied Biosystems/
Ambion) using Lipofectamine 2000 in OptiMEM according to the
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reagents were removed and 2 mL of EGM-2 medium added.
Cells were used in experiments 72 h later. CRACR2A siRNA 1 was
(50–30) CAACAAAUCAAAAGUGAGAtt, CRACR2A siRNA 2 was GGA-
GUUCACUACUGGAUUUtt, and Orai1 siRNA was GGGAAGAGGAU
UUUUAUAAtt. Control siRNA was a 19-bp scrambled sequence
with no signiﬁcant homology to human gene sequences (Silencer
Negative Control number 1, Ambion).
2.4. Western blotting
Transfected HUVECs were harvested in PBS and lysed in buffer
containing 0.5% NP40, 10 ml Tris (pH 8), 150 mM NaCl, 0.5 mM
EDTA, protease inhibitor cocktail (Fermentas) and 1 mM phen-
ylmethanesulfonylﬂuoride (PMSF). Equal protein amounts were
loaded on 10% gels and resolved by electrophoresis. Products were
transferred onto PVDF membranes and incubated overnight with
primary anti-CRACR2A antibody and anti-b-actin antibody used
at 1:800 and 1:2000 dilution respectively. Anti-CRACR2A was vis-
ualised using horse radish peroxidase conjugated goat anti-rabbit
secondary antibody and anti-actin was visualised with anti-mouse
secondary antibody and SuperSignal Femto detection reagent (Per-
Bio Science). ImageJ was used to quantify protein band densities.
2.5. RT-PCR
RNA was extracted using TRI reagent (Sigma). Reverse
transcription using Reverse Transcriptase (Applied Biosystems),
followed by real-time PCR using SYBR green was performed using
a LightCycler (Roche). The forward primer was (50–30) CGTCATGTA
CGATCTCAC and the reverse primer GTGACCAGAGTAGGCG.
2.6. Cloning
Reverse transcription of HUVEC total RNA was performed using
Superscript II Reverse Transcriptase (Invitrogen) and a CRAC2RA-L
gene speciﬁc primer (50 GGTATGGCTGACCTTGTAGGACCCTATCA).
CRACR2A-L sequence was ampliﬁed from the enriched cDNA using
GoTaq Green (Promega) and cloning primers (Forward: 50 GAT-
CCGCTAGCGCTACACCATGGCTGCCCCTGACGGG, reverse: 50 GGTAT
GGCTGACCTTGTAGGACCCTATCA) designed to be compatible with
the GFP vector using Infusion-HD enzyme (Clontech). PCR reaction
conditions were: 95 C for 2 min (initial denaturation stage)
followed by 40 cycles of: 95 C for 30 s, 53 C for 30 s, 73 C for
2.5 min followed by a ﬁnal extension at 73 C for 5 min.
CRAC2RA-L sequence was further ampliﬁed by a second round of
PCR using the high ﬁdelity DNA polymerase Phusion (Thermosci-
entiﬁc). Constructs were generated using the kanamycin resistant
eGFP-C1 plasmid (Clontech). Constructs were veriﬁed by sequencing
(Beckman Coulter).
2.7. Co-culture tube formation assay
Normal Human Dermal Fibroblasts were seeded into a 96 well
plate (Greiner) at a density of 2  103 cells/well and incubated at
37 C in a 5% CO2 incubator for 72 h. The cell culture medium
was removed and HUVECs at a density of 5.4  104 cells/well were
seeded on top of the ﬁbroblasts in endothelial cell growth medium
containing 3 ng/mL vascular endothelial growth factor and 2% FBS.
Co-cultures were incubated for 7 days then ﬁxed with ice-cold
methanol for 10 min. Nonspeciﬁc binding sites were blocked with
5% donkey serum (in PBS) for 30 min at 37 C. HUVEC tubes were
visualised by staining with a primary monoclonal mouse
anti-human CD31 antibody (1:500 in 1% donkey serum for 1 h at
room temperature). After 3 washes in PBS a secondary Alexa Fluor
488 antibody was added for 1 h at room temperature. Plates wereimaged using an IncuCyte (Essen Bioscience) and tube formation
was quantiﬁed using the IncuCyte angiogenesis v2.0 software.
2.8. Reagents and antibodies
Fura-2 AM and Lipofectamine 2000 were obtained from Invitro-
gen. Polyclonal rabbit anti-CRACR2A-L antibody (15206-1-AP)
from Proteintech group was used at 1:800 dilution. b-Actin (C4)
mouse monoclonal IgG1 antibody (sc-47778) and bovine
anti-mouse IgG-HRP (sc-2371) antibody were from Santa Cruz
Biotechnology and used at 1:2000 and 1:10,000 respectively. Goat
anti-rabbit HRP-conjugated antibody from Sigma was used at
1:10,000. Peroxidase-conjugated AfﬁniPure donkey anti-rabbit
IgG (H+L) (705-035-003) from Jackson ImmunoResearch Labs Inc.
was used at 1:10,000. Thapsigargin was from Sigma.
2.9. Data analysis
Data were analysed and ﬁgures prepared using Origin 7.5 soft-
ware (OriginLab Corporation). For FlexStation experiments data are
presented as n/N, which indicates the number of independent
experiments (n) and the number of individual wells (replicates)
in the 96-well plate. For Western blot data n is the number of inde-
pendent experiments. Paired data sets were compared using two-
tailed Student’s t-tests and expressed as mean ± standard error of
the mean (s.e.m.). P < 0.05 indicated statistically signiﬁcant differ-
ence (*).3. Results
Intracellular Ca2+ was recorded from human umbilical vein
endothelial cells (HUVECs) to observe Ca2+ release evoked by
thapsigargin (TG) in the absence of extracellular Ca2+ and then
CRAC channel-mediated Ca2+ entry as extracellular Ca2+ was added
back (Fig. 1A). Unexpectedly, transfection with short interfering
RNA (siRNA) targeted to CRACR2A failed to affect Ca2+ release or
Ca2+ entry (Fig. 1A and B). In contrast, siRNA targeted to Orai1
suppressed Ca2+ entry but not Ca2+ release, consistent with
Orai1-dependent CRAC channels mediating Ca2+ entry (Fig. 1C
and D). The data suggest that CRACR2A is unimportant for CRAC
channels in these cells.
An explanation for the above data could be that CRACR2A is not
expressed. Indeed, anti-CRACR2A antibody failed to detect protein
of 45 kDa (Fig. 2A), which is the expected mass of CRACR2A [3].
However, a doublet around 95 kDa was labelled by the antibody
and the lower of these two bands was depleted by two different
siRNAs targeted to CRACR2A (Fig. 2A and B). The upper band
may reﬂect an unrelated protein, labelled non-speciﬁcally by the
antibody. The data suggest that CRACR2A is expressed in endothe-
lial cells but that it occurs at about twice the expected molecular
mass.
To obtain an explanation for the larger mass we searched
genome sequence databases and found that the gene encoding
CRACR2A, EFCAB4B, is predicted to be alternatively spliced to give
two variants. Alignment of the predicted amino acid sequences of
the short (CRACR2A) and long (CRACR2A-L) variants revealed that
the N-terminal components are identical but that CRACR2A-L con-
tains a distinct long C-terminus bearing little or no similarity to
CRACR2A (Fig. S1). The analysis suggests that the 95 kDa protein
might be CRACR2A-L.
To determine if endothelial cells express transcript encoding
CRACR2A-L we performed full-length cloning based on the
predicted sequence and using HUVEC mRNA. Sequencing showed
the clone to be identical to the sequence predicted to encode
CRACR2A-L except for one codon for an additional amino acid
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Fig. 1. No effect of CRACR2A siRNA on CRAC channels in endothelial cells. (A) Mean ± s.e.m. paired intracellular Ca2+ data for human umbilical vein endothelial cells (HUVECs)
transfected with control siRNA or CRACR2A siRNA (N = 4 each). Thapsigargin (TG, 1 lM) was added in the absence of extracellular Ca2+ before 2 mM Ca2+ was returned to the
medium. (B) Summary data for 5 independent experiments of the type illustrated in (A). (C, D) As for (A, B) except using Orai1 siRNA in place of CRACR2A siRNA (n/N = 2/9).
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Fig. 2. Detection of long but not short CRACR2A in endothelial cells. (A) Western blot probed with anti-CRACR2A antibody for HUVECs transfected with control or CRACR2A
siRNA. S indicates the expected mass for CRACR2A (short variant). L indicates a larger protein (long variant) which was depleted by CRACR2A siRNA. Equal total protein was
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was also detected in human dermal microvascular endothelial cells
and RT-PCR detected mRNA encoding CRACR2A-L in endothelial
cells from 6 additional sources (Fig. 2C). The data suggest that
the long variant, CRACR2A-L, is the variant of endothelial cells.
Analysis of the distinct long C-terminus of CRACR2A-L indicated
G boxes and other sequence similarities characteristic of Rab
GTPases (Fig. 3). Construction of a dendrogram placed CRACR2A-L
as a previously unrecognised member of the large Rab protein
family (Fig. S2). It is relatively unusual amongst the Rab proteins
in containing EF hands (Fig. 3), Ca2+-binding motifs that have been
shown to be functional in CRACR2A [3].
To determine if CRACR2A-L has functional signiﬁcance in
endothelial cells we performed an assay in which HUVECs form
tube, capillary-like, structures on a bed of ﬁbroblasts, mimicking
aspects of angiogenesis (Fig. 4A). Depletion of CRACR2A-L did not
prevent tube formation but reduced the overall length of tubes
and the number of branch points (Fig. 4B and C). The data suggest
that CRACR2A-L is a functional protein of endothelial cells.4. Discussion
The results suggest a previously unrecognized protein of the
Rab GTPase family. It is encoded by the same gene as CRACR2A, a
protein expressed in T cells and regulating CRAC channels, but
alternative splicing enables a long C-terminal extension and total
protein of about twice the size of CRACR2A. We refer to it as
CRACR2A-L. The N-terminus is identical to CRACR2A. It is the* ** *
G2
MAAPDGRVVSRPQRLGQGSGQGPKGSGACLH
DAEGKGFIARKDMQRLHKELPLSLEELEDVF
QEDAGEQVAQRHEEKVYLSRGDEDLGDMGED
KKEEPHLLSNFEDFLTRIISQLQEAHEEKNE
EQFLLKDTERFQARSQELEQKLLCKEQELEQ
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Fig. 3. Sequence and Rab GTPase domains of CRACR2A-L. (A) Amino acid sequence for
conserved in Rab proteins. (B) Diagram indicating features of CRACR2A-L (upper) and CR
are the amino acid positions in the total sequence.additional C-terminal sequence that makes it a member of the
Rab GTPase family. CRACR2A-L is expressed in endothelial cells,
whereas CRACR2A is not. CRACR2A-L has no effect on CRAC
channels in these cells and so we assume that the C-terminal
sequence directs the protein away from these channels.
Rab proteins comprise the largest sub-group of the RAS super-
family and are best known for roles in intracellular trafﬁcking
[5,6]. Most Rab proteins are 20–25 kDa [7] and thus smaller than
CRACR2A-L. Rab44 and Rab45 are, by contrast, similar in size to
CRACR2A-L at 108 and 83 kDa [5,8]. As in CRACR2A-L the extra
length appears to exist for incorporation of EF-hands and thus
Ca2+ regulation. We speculate therefore that CRACR2A-L might be
a mechanism for coupling cytosolic Ca2+ elevation to protein
trafﬁcking which in turn impacts on endothelial tube formation
and potentially other as yet unidentiﬁed downstream processes.
It would be challenging to test this idea through studies of
tube formation because the impact of CRACR2A-L on this process
was relatively small. Therefore, it will be important to identify
speciﬁc downstream effectors and other downstream implications
of CRACR2A-L in order to understand its suggested integrative
role.
It is intriguing why the gene encoding this CRACR2A-L protein
would also be capable of generating the shorter CRACR2A protein
which regulates the Ca2+-permeable CRAC channels [3]. Although
there was only CRACR2A-L in endothelial cells, regulation of
alternative splicing may lead to co-expression of CRACR2A and
CRACR2A-L in some contexts. In such contexts, CRACR2A would
be expected to have a positive effect on CRAC channels, elevating
the cytosolic Ca2+ concentration and potentially modulating the*** **
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Fig. 4. CRACR2A-L depletion suppresses endothelial tube formation. (A) Images of HUVECs labelled with anti-CD31 antibody (green) after forming tube-like structures on
ﬁbroblasts, which were not labelled. HUVECs were transfected with control siRNA or CRACR2A siRNA. (B) Summary histograms showing the effects of CRACR2A siRNA on tube
length and number of branch points (n/N = 3/21). (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this article.)
402 L.A. Wilson et al. / Biochemical and Biophysical Research Communications 456 (2015) 398–402function of CRACR2A-L, integrating Ca2+-signalling and protein
trafﬁcking via a single gene.
We observed mild but signiﬁcant positive impact of CRACR2A-L
on endothelial cell remodelling. Additional functions of CRACR2A-L
can be expected to emerge, however, and it would be premature to
suggest that regulation of endothelial cell remodelling is its pri-
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